2026-10-14T02:10:35Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33959630 2026-09-21T18:20:50Z category_4 category_12 category_15 category_19 category_21 category_64 category_122 category_132 category_134 portal_5 item_type_3 month_year_09_2026

<p>Primary and key secondary outcomes for the intention-to-treat population (n = 139).</p> Charles J. Gerardo (3094953) Ashish Bhalla (90214) Chitta R. Mohanty (25085075) Badal K. Sahu (25085078) Surendra Kumar (33312) Suneil Agrawal (25085081) Manu Ayyan S (22177168) Eileen Shu (6490865) Travis Deuson (25085084) Madhu Kumar R (25085087) Norman L. Beatty (14279409) Peter D. Akpunonu (25085090) Farshad M. Shirazi (21626194) Sarah Watkins (6281345) Anne-Michelle Ruha (16919210) Shawn M. Varney (20839285) Anil K. Goel (25085093) Medhavi Gautam (25085096) Justin Arnold (19452067) Chanaveerappa Bammigatti (10164649) Samuel J. Francis (25085099) Suresh Selvam (25085102) Harish Kumar (363551) Adiel Aizenberg (25085105) Andrew Micciche (25085108) Rylee S. Bledsoe (25085111) Ginger Boatright (25085114) Suraj C. Oomman (25085117) Stephen P. Samuel (25085120) Janet T. Wittes (25085123) Rebecca W. Carter (25085126) Matthew R. Lewin (11532265) Timothy F. Platts-Mills (4732398) Biochemistry Cell Biology Neuroscience Pharmacology Biotechnology Cancer Mental Health Infectious Diseases Virology snake species responsible evaluated intravenous followed disproportionately affecting low requires intravenous administration 000 &# 8211 nct05717062 ), patients care including antivenom late adjunctive varespladib average 7 hours 66 placebo ). adjunctive varespladib adjunctive therapy 000 deaths 000 cases sss ). 7 ). 6 ). hospitalized patients 140 patients several hours 6 hours 2 hours xlink "> venom composition varespladib vs study drug resource regions receive varespladib randomly assigned primary endpoint permanent disability oral varespladib october 19 estimated 81 day 14 clinical manifestations associated differences approved treatment antivenom administration among viper among elapid 73 varespladib <p>Primary and key secondary outcomes for the intention-to-treat population (n = 139).</p> 2026-09-21T18:02:11Z Dataset Dataset 10.1371/journal.pntd.0014736.t002 https://figshare.com/articles/dataset/_p_Primary_and_key_secondary_outcomes_for_the_intention-to-treat_population_n_139_p_/33959630 CC BY 4.0